Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

Author: Chen Jianping   Smith Melissa   Kolinsky Kenneth   Adames Violeta   Mehta Nila   Fritzky Luke   Rashed Mohammad   Wheeldon Eric   Linn Michael   Higgins Brian  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.59, Iss.5, 2007-04, pp. : 651-659

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content